ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Holdings Boosted by American Century Companies Inc.

American Century Companies Inc. boosted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 99.2% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 99,831 shares of the specialty pharmaceutical company’s stock after purchasing an additional 49,717 shares during the quarter. American Century Companies Inc. owned about 0.48% of ANI Pharmaceuticals worth $6,357,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Texas Permanent School Fund Corp raised its stake in shares of ANI Pharmaceuticals by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock valued at $912,000 after purchasing an additional 172 shares in the last quarter. Louisiana State Employees Retirement System lifted its stake in shares of ANI Pharmaceuticals by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock worth $490,000 after acquiring an additional 200 shares during the period. Arizona State Retirement System boosted its holdings in shares of ANI Pharmaceuticals by 4.7% in the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock valued at $299,000 after acquiring an additional 211 shares in the last quarter. Simplicity Wealth LLC raised its holdings in ANI Pharmaceuticals by 3.5% during the second quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock worth $429,000 after purchasing an additional 227 shares in the last quarter. Finally, California State Teachers Retirement System raised its holdings in ANI Pharmaceuticals by 1.5% during the first quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock worth $1,118,000 after purchasing an additional 233 shares in the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ANIP shares. HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Raymond James upped their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Finally, Truist Financial reissued a “hold” rating and set a $60.00 target price (down from $80.00) on shares of ANI Pharmaceuticals in a research note on Wednesday, September 11th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $78.80.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 14,257 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total transaction of $900,472.12. Following the completion of the sale, the chief operating officer now directly owns 635,363 shares in the company, valued at approximately $40,129,527.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction on Monday, July 1st. The stock was sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the completion of the sale, the senior vice president now owns 193,226 shares of the company’s stock, valued at $12,258,257.44. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Muthusamy Shanmugam sold 14,257 shares of the business’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total value of $900,472.12. Following the completion of the transaction, the chief operating officer now owns 635,363 shares in the company, valued at approximately $40,129,527.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,007 shares of company stock valued at $2,911,790. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $58.52 on Wednesday. The company has a 50-day moving average of $60.89 and a two-hundred day moving average of $63.58. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of 36.58 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. ANI Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.07. The firm had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The company’s quarterly revenue was up 18.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.06 EPS. On average, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.